“…Thus, poor bioavailability is the major weak point of curcumin and has been the main challenge for physicians seeking to verify the therapeutic efficacy of this promising agent in clinical trials. Therefore, many efforts have been made to improve its bioavailability through several approaches including innovative drug delivery systems (liposomes, nanoparticles and phospholipids) (Anand et al, 2010;Antony et al, 2008;Bisht et al, 2007;Das et al, 2010;Gupta et al, 2009;Koppolu et al, 2010;Li et al, 2005;Liu et al, 2006;Marczylo et al, 2007;Mukerjee & Vishwanatha, 2009;Sahu et al, 2008;Shaikh et al, 2009;Sou et al, 2008;Takahashi et al, 2009), or the development of new curcumin analogues Mosley et al, 2007;Ohori et al, 2006;Sato et al, 2011). A nanoparticlebased drug delivery system is effective in improving the water solubility of hydrophobic agents like curcumin, and the development of at least 8 different types of nanoparticlebased curcumin have been published up to this point (Anand et al, 2010;Bisht et al, 2007; Das et al, 2010;Gupta et al, 2009;Mukerjee & Vishwanatha, 2009;Shaikh et al, 2009;Sou et al, 2008).…”